Chronic kidney disease: pathophysiological role of dysbiosis of intestine and renoprotective effectiveness of interventions concerning its modulation


如何引用文章

全文:

详细

The review presents data concerning disorders of quantitative and qualitative content of intestinal microbiota in patients with chronic kidney disease. The causes enhancing development of intestinal dysbiosis and sub-clinical inflammation under chronic disease of kidneys are considered. The results of preliminary studies concerning investigation of particular approaches to therapy of chronic kidney disease directed to restoring of intestinal symbiosis and neutralization of bacterial endotoxins and adsorption of uremic toxins of intestinal origin are presented.

作者简介

K. Aytbaev

National center of cardiology and therapy

The research institute of molecular biology and medicine under 720040, Beshkek, the Republic of Kirghizia

I. Murkamilov

I.K. Akhunbaiev Kirghizia state medical academy

Email: murkamilov.i@mail.ru
assistant of the chair of therapy of general practice with course of family medicine, physician-nephrologist Beshkek, the Republic of Kirghizia

R. Kaliev

I.K. Akhunbaiev Kirghizia state medical academy

The chair of therapy of general practice with course of family medicine Beshkek, the Republic of Kirghizia

参考

  1. De Filippo C., Cavalieri D., Di Paola M., Ramazzotti M., Poullett J.B., Massart S. et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. U S A. 2010; 107 (33): 14691-6.
  2. Ley R.E., Tumbaugh P.J., Klein S., Gordon J.I. Microbial ecology: Human gut microbes associated with obesity. Nature. 2006; 444(7122): 1022-3.
  3. Qin J., Li Y., Cai Z., Li S., Zhu J., Zhang F. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012; 490(7418): 55-60.
  4. Frank D.N., Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel disease. Proc. Natl. Acad. Sci. U.S.A. 2007; 104(34): 13780-5.
  5. Wang Z., Klipfell E., Bennett B.J., Koeth R., Levison B.S., Dugar B. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011; 472(7341): 57-63.
  6. Vaziri N.D., Wong J., Pahl M., Piceno Y.M., Yuan J., DeSantis T.Z. et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013; 83(2): 308-15.
  7. Wu I.W., Hsu K.H., Lee C.C., Sun C.Y., Hsu H.J., Tsai C.J. et al. PCresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol. Dial. Transplant. 2011; 26(3): 938-47.
  8. Hida M., Aiba Y., Sawamura S., Suzuki N., Satoh T., Koga Y. et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 1996; 74(2): 349_55.
  9. Aronsson B., Barany P., Nord C.E., Nystrom B., Stenvinkel P. Clostridium difficile-associated diarrhea in uremic patients. Eur. J. Clin. Microbiol. 1987; 6(3): 352-6.
  10. Kang J.Y. The gastrointestinal tract in uremia. Dig. Dis. Sci. 1993; 38(2): 257-68.
  11. Hatch M., Freel R.W., Vaziri N.D. Intestinal excretion of oxalate in chronic renal failure. J. Am. Soc. Nephrol. 1994; 5(6): 1339-43.
  12. Jemberg C., Lofmark S., Edlund C., Jansson J.K. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology. 2010; 156(Pt.11): 3216-23.
  13. Wu M.J., Chang C.S., Cheng C.H., Chen C.H., Lee W.C., Hsu Y.H. et al. Colonic transit time in long-term dialysis patients. Am. J. Kidney Dis. 2004; 44(2): 322-7.
  14. Goraya N., Wesson D.E. Acid-base status and progression of Chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2012; 21(5): 552-6.
  15. Niebauer J., Volk H.D., Kemp M., Dominguez M., Schumann R.R., Rauchhaus M. et al. Endotoxin and immune activation in chronic heart failure: A prospective cohort study. Lancet. 1999; 353(9167): 1838-42.
  16. Liguori L. Iron protein succinylate in the treatment of iron deficiency: Controlled, double-blind, multicenter clinical trial on over 1,000 patients. Int. Clin. Pharmacol. Ther. Toxicol. 1993; 31(3): 103-23.
  17. Almqutst H.J., Stokstan E.L. The Gizzard factor of the chick. J. Nutr. 1937; 13: 339-50.
  18. Szeto C.C., Kwan B.C., Chow K.M., Lai K.B., Chung K.Y., Leung C.B. et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin. J. Am. Soc. Nephrol. 2008; 3(2): 431-6.
  19. Mclntyre C.W., Harrison L.E., Eldehni M.T., Jefferies H.J., Szeto C.C., John S.G. et al. Circulating endotoxemia: A novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2011; 6(1): 133-41.
  20. Aronov P.A., Luo F.J., Plummer N.S., Quan Z., Holmes S., Hostetter T.H. et al. Colonic contribution to uremic solutes. J. Am. Soc. Nephrol. 2011; 22(9): 1769-76.
  21. Lin C.J., Chen H.H., Pan C.F., Chuang C.K., Wang T.J., Sun F.J. et al. P-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J. Clin. Lab. Anal. 2011; 25(3): 191-7.
  22. Barreto F.C., Barreto D.V., Liabeuf S., Meert N., Glorieux G., Temmar M. et al. European UREMIC Toxin Work Group (EUTox): Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol. 2009; 4(10): 1551-8.
  23. Bammens B., Evenopoel P., Keuleers H., Verbeke K., Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int. 2006; 69(6): 1081-7.
  24. Silk D.B., Davis A., Vulevic J., Tzortzis G., Gibson G.R. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2009; 29(5): 508-18.
  25. Pylkas A.M., Juneja L.R., Slavin J.L. Comparison of different fibers for in vitro production of short chain fatty acids by intestinal microflora. J. Med. Food. 2005; 8(1): 113-6.
  26. Krishnamurthy V.M., Wei G., Baird B.C., Murtaugh M., Chonchol M.B., Raphael K.L. et al. High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int. 2012; 81(3): 300-6.
  27. Meijers B.K., De Preter V., Verbeke K., Vanrenterghem Y., Evenopoel P. p-Cresyl sulfate serum concentration in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol. Dial. Transplant. 2010; 25(1): 219-24.
  28. Drucker D.J. The biology of incretin hormones. Cell. Metab. 2006; 3(3): 153-65.
  29. Delzenne N.M., Cani P.D., Daubioul C., Neyrinck A.M. Impact of inulin and oligofructose on gastrointestinal peptides. Br. J. Nutr. 2005; 93(Suppl.1): S157-61.
  30. Food and Agriculture Organization of the United Nations (FAO). Health and nutritional properties of probiotics in food including powder milk with live lactic acidbacteria. 2001. Available at: http://www.who.int/foodsafety/fs_management/Probiotics/en. (Accessed 30 October 2013).
  31. Rastall R.A., Gibson G.R., Gill H.S., Guarner F., Klaenhammer T.R., Pot B. et al. Modulation of the microbial ecology of the human colon by probiotics, prebiotics and synbiotics to enhance human health: An overview of enabling science and potential applications. FEMS Microbiol. Ecol. 2005; 52(2): 145-52.
  32. Konstantinov S.R., Smidt H., de Vos W.M., Bruijns S.C., Singh S.K., Valence F. et al. S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc. Natl. Acad. Sci. U.S.A. 2008; 105(49): 19474-9.
  33. Van Baarlen P., Troost F.J., van Hemert S., van der Meer C., de Vos W.M., de Groot P.J. et al. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc. Natl. Acad. Sci. U.S.A. 2009; 106(7): 2371-6.
  34. Ranganathan N., Patel B., Ranganathan P., Marczely J., Dheer R., Chordia T. et al. Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats. Scientifi c World Journal. 2005; 5: 652-60.
  35. Chen L., Liu W., Li Y., Luo S., Liu Q., Zhong Y. et al. Lactobacillus acidophilus ATCC 4356 attenuates the atherosclerotic progression through modulation of oxidative stress and inflammatory process. Int. Immunopharmacol. 2013; 17(1): 108-15.
  36. Prakash S., Chang T.M. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat. Med. 1996; 2(8): 883-7.
  37. Evenopoel P., Bammens B., Verbeke K., Vanrenterghem Y. Acarbose treatment lowers generation and serum concentration of the protein-bound solute p-cresol: a pilot study. Kidney Int. 2006; 70(1): 192-8.
  38. Manichanh C., Reeder J., Gilbert P., Varela E., Llopis M., Antolin M. et al. Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. Genome Res. 2010; 20(10): 1411-9.
  39. Persky S.E., Brandt L.J. Treatment of recurrent Clostridium difficileassociated diarrhea by administration of donated stool directly through a colonoscope. Am. J. Gastroenterol. 2000; 95(11): 3283-5.
  40. Hawrelac J.A., Cattley T., Myers S.P. Essential oils in the treatment of intestinal dysbiosis: A preliminary in vitro study. Altern. Med. Rev. 2009; 14(4): 380-4.
  41. Perianayagam M.C., Jaber B.L. Endotoxin-binding affinity of sevelamer hydrochloride. Am. J. Nephrol. 2008; 28(5): 802-7.
  42. Sun P.P., Perianayagam M.C., Jaber B.L. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: A pilot crosssectional study. J. Ren. Nutr. 2009; 19(5): 432-8.
  43. Navarro-Gonzales J.F, Mora-Fernandez C., Muros de Fuentes M., Donate-Correa J., Cazana-Perez V., Garcia-Perez J. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2011; 6(9): 2272-9.
  44. Bortoluci K.R., Medzhitov R. Control of infection by pyroptosis and autophagy: role of TLR and NLR. Cell Mol. Life Sci. 2010; 67(10): 1643-51.
  45. Yohnson D.A. Synthetic TLP4-active glycolipids as vaccine adiuvants and stand-alone immunotherapeutics. Curr. Top. Med. Chem. 2008; 8(2): 64-79.
  46. Barochia A., Solomon S., Cui X., Natanson C., Eichacker P.Q. Eritoran tetrasodium (E5564) treatment for sepsis: Review of preclinical and clinical studies. Expert. Opin. Drug. Metab. Toxicol. 2011; 7(4): 479-94.
  47. Fort M.M., Mozaffarian A., Stover A.G., Correia J.S., Johnson D.A., Crane R.T. et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J. Immunol. 2005; 174(10): 6416-23.
  48. Lynn M., Rossignol D.P., Wheeler J.L., Kao R.J., Perdomo C.A., Noveck R. et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J. Infect. Dis. 2003; 187(4): 631-9.
  49. Neal M.D., Jia H., Eyer B., Good M., Guerriero C.J., Sodhi C.P. et al. Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors. PLoS One. 2013; 37(6): 518-25.
  50. Vaziri N.D., Yuan J., Khazaeli M., Masuda Y., Ichii H., Liu S. Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption. Am. J. Nephrol. 2013; 37(6): 518-25.
  51. Miyazaki T., Aoyama I., Ise M., Seo H., Niwa T. An oral sorbent reduces overloud of indoxyl sulphate and gene expression of TGF-beta 1 in uraemic rat kidneys. Nephrol. Dial. Transplant. 2000; 15(11): 1773-81.
  52. Niwa T., Emoto Y., Maeda K., Uehara Y., Yamada N., Shibata M. Oral sorbent suppresses accumulation of albumin-bound indoxyl sulphate in serum of haemodialysis patients. Nephrol. Dial. Transplant. 1991; 6(2): 105-9.
  53. Niwa T., Nomura T., Sugiyama S., Miyazaki T., Tsukushi S., Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: An oral absorbent lowers indoxyl sulphate levels in undialyzed uremic patients. Kidney Int. Suppl. 1997; 62: S23-8.
  54. Hatakeyama S., Yamamoto H., Okamoto A., Imanishi K., Tokui N., Okamoto T. et al. Effect of an Oral Adsorbent, AST-120, on Dialysis Initiation and Survival in Patients with Chronic Kidney Disease. Int. J. Nephrol. 2012; 2012: 376128.
  55. Abe M., Matsuda M., Kobayashi H., Miyata Y., Nakayama Y., Komuro R. et al. Effects of statins on adipose tissue inflammation. Their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler. Thromb. Vasc. Biol. 2008; 28(5): 871-7.
  56. Chansrichavala P., Chantharaksri U., Sritara P., Ngaosuwankul N., Chaiyaroj S.C. Atorvastatin affects TLR4 clustering via lipid raft modulation. Int. Immunopharmacol. 2010; 10(8): 892-9.
  57. John S.G., Owen P.J., Harrison L.E., Szeto C.C., Lai K.B., Li P.K. et al. The impact of antihypertensive drug therapy on endotoxemia in elderly patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2011; 6(10): 2389-94.

版权所有 © Eco-Vector, 2016


 


##common.cookie##